Alon Ben-Noon Acquires 250,000 Shares of NeuroSense Therapeutics (NASDAQ:NRSN) Stock

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) CEO Alon Ben-Noon bought 250,000 shares of the stock in a transaction that occurred on Tuesday, June 16th. The stock was bought at an average price of $0.80 per share, with a total value of $200,000.00. Following the completion of the purchase, the chief executive officer directly owned 4,534,233 shares in the company, valued at $3,627,386.40. This represents a 5.84% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

NeuroSense Therapeutics Trading Up 14.1%

Shares of NeuroSense Therapeutics stock opened at $0.80 on Friday. NeuroSense Therapeutics Ltd. has a 12-month low of $0.63 and a 12-month high of $2.52. The firm has a market capitalization of $26.20 million, a price-to-earnings ratio of -1.49 and a beta of 1.56. The firm’s 50 day simple moving average is $0.78 and its two-hundred day simple moving average is $0.85.

Analyst Ratings Changes

NRSN has been the topic of several research reports. D. Boral Capital reissued a “buy” rating and issued a $14.00 target price on shares of NeuroSense Therapeutics in a research report on Wednesday, April 8th. Roth Mkm began coverage on NeuroSense Therapeutics in a report on Tuesday, March 10th. They issued a “buy” rating and a $3.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NeuroSense Therapeutics in a research note on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.50.

Hedge Funds Weigh In On NeuroSense Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in shares of NeuroSense Therapeutics in the 2nd quarter valued at about $54,000. Squarepoint Ops LLC grew its holdings in NeuroSense Therapeutics by 91.0% during the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after acquiring an additional 45,450 shares during the period. Two Sigma Investments LP acquired a new stake in NeuroSense Therapeutics during the third quarter worth about $26,000. Finally, Yorkville Advisors Global LP acquired a new stake in NeuroSense Therapeutics during the fourth quarter worth about $77,000. Hedge funds and other institutional investors own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.